Unresectable Leiomyosarcoma: Clinical Trials

4 trials for Unresectable Leiomyosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed, 1 recruiting. 4 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Terminated 2, Completed 1, Recruiting 1
Phase 22Terminated 2

Follow Unresectable Leiomyosarcoma: new trials by email Literature Review of Unresectable Leiomyosarcoma trials Research Report on Unresectable Leiomyosarcoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma
Phase 1RecruitingNational Cancer Institute (NCI)302024-02-062026-11-04
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center352017-09-282022-04-29
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma
Phase 1CompletedOHSU Knight Cancer Institute162017-03-102023-08-16
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)1512015-11-302022-08-23

Narrower conditions

Dermatofibrosarcoma (3)  ·  Histiocytoma, Malignant Fibrous (3)  ·  Leiomyosarcoma (3)  ·  Liposarcoma (3)  ·  Sarcoma, Synovial (3)  ·  Neurofibrosarcoma (2)  ·  Sarcoma (2)  ·  Disorders of Sex Development (1)  ·  Fibrosarcoma (1)  ·  Hemangiosarcoma (1)

Broader conditions

Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Connective and Soft Tissue (4)  ·  Histiocytoma (3)  ·  Neoplasms, Adipose Tissue (3)  ·  Neoplasms, Connective Tissue (3)  ·  Neoplasms, Fibrous Tissue (3)  ·  Neoplasms, Muscle Tissue (3)  ·  Fibrosarcoma (2)  ·  Neoplasms, Nerve Tissue (2)  ·  Nerve Sheath Neoplasms (2)  ·  Nervous System Diseases (2)  ·  Nervous System Neoplasms (2)  ·  Neurofibroma (2)  ·  Neuromuscular Diseases (2)

Interventions

Doxorubicin (2)  ·  Biopsy (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  Trabectedin (1)  ·  avelumab (1)  ·  liposomal doxorubicin (1)  ·  pazopanib (1)  ·  peposertib (1)  ·  ribociclib (1)  ·  sapanisertib (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Fred Hutchinson Cancer Center (1)  ·  OHSU Knight Cancer Institute (1)

Countries

United States (4)

Top investigators

Candace L Haddox (1)  ·  Lara E Davis (1)  ·  Seth Pollack (1)  ·  William D Tap (1)

NIH funding

P30CA015704 (1), U10CA180821 (1), UM1CA186709 (1)